Moleculin Biotec Financials
This page shows Moleculin Biotec (MBRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Moleculin Biotec passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Moleculin Biotec generates $0.68 in operating cash flow (-$22.7M OCF vs -$33.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Moleculin Biotec's EBITDA was -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.7% from the prior year.
Moleculin Biotec reported -$33.6M in net income in fiscal year 2025. This represents a decrease of 54.2% from the prior year.
Cash & Balance Sheet
Moleculin Biotec generated -$22.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 4.7% from the prior year.
Moleculin Biotec held $8.9M in cash against $0 in long-term debt as of fiscal year 2025.
Moleculin Biotec had 5M shares outstanding in fiscal year 2025. This represents an increase of 57.9% from the prior year.
Margins & Returns
Moleculin Biotec's ROE was -223.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 29.5 percentage points from the prior year.
Capital Allocation
Moleculin Biotec invested $15.9M in research and development in fiscal year 2025. This represents a decrease of 10.4% from the prior year.
Moleculin Biotec invested $13K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.
MBRX Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.7M+3.8% | $3.6M+4.8% | $3.4M | N/A | $4.9M+20.6% | $4.1M-3.8% | $4.3M | N/A |
| SG&A Expenses | $2.1M+2.7% | $2.1M-15.6% | $2.5M | N/A | $2.2M+5.2% | $2.1M-13.7% | $2.4M | N/A |
| Operating Income | -$5.9M-3.3% | -$5.7M+3.8% | -$5.9M | N/A | -$7.1M-15.4% | -$6.2M+7.4% | -$6.7M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$25.4M-42.6% | -$17.8M-201.6% | -$5.9M | N/A | -$7.0M-16.8% | -$6.0M+6.4% | -$6.4M | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MBRX Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.4M-5.7% | $21.6M+2.8% | $21.0M+24.2% | $16.9M-27.7% | $23.4M-8.5% | $25.6M-17.1% | $30.8M-19.3% | $38.2M |
| Current Assets | $7.9M-13.1% | $9.1M-2.8% | $9.3M+79.8% | $5.2M-55.2% | $11.6M-15.5% | $13.7M-27.6% | $19.0M-27.8% | $26.3M |
| Cash & Equivalents | $6.7M-11.3% | $7.6M-2.1% | $7.7M+80.4% | $4.3M-54.5% | $9.4M-13.3% | $10.8M-35.5% | $16.8M-28.6% | $23.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $47.3M+87.8% | $25.2M+248.6% | $7.2M+26.3% | $5.7M-4.4% | $6.0M-24.0% | $7.9M-15.0% | $9.3M-23.8% | $12.1M |
| Current Liabilities | $5.7M-28.2% | $7.9M+14.7% | $6.9M+28.7% | $5.4M-4.2% | $5.6M-2.7% | $5.7M+6.3% | $5.4M-20.6% | $6.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$26.9M-650.9% | -$3.6M-126.0% | $13.8M+23.0% | $11.2M-35.6% | $17.4M-10.3% | $19.4M-22.3% | $25.0M-19.2% | $30.9M |
| Retained Earnings | -$221.6M-12.9% | -$196.2M-10.0% | -$178.3M-3.4% | -$172.4M-13.8% | -$151.5M-7.5% | -$140.9M-3.2% | -$136.6M-3.8% | -$131.6M |
MBRX Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M-29.4% | -$5.6M-22.3% | -$4.6M+10.2% | -$5.1M+16.8% | -$6.1M-2.8% | -$5.9M+11.4% | -$6.7M-37.2% | -$4.9M |
| Capital Expenditures | $0 | $0 | $0 | $0 | $0-100.0% | $13K | $0-100.0% | $81K |
| Free Cash Flow | -$7.2M-29.4% | -$5.6M-22.3% | -$4.6M+10.2% | -$5.1M+16.8% | -$6.1M-2.5% | -$6.0M+11.2% | -$6.7M-34.9% | -$5.0M |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0+100.0% | -$13K | $0+100.0% | -$81K |
| Financing Cash Flow | $6.4M+17.6% | $5.4M-32.2% | $8.0M+799800.0% | $1K-100.0% | $4.7M+18736.0% | -$25K | $0-100.0% | $4.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MBRX Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -42.8% | N/A | -40.3%-9.3pp | -31.0%-5.3pp | -25.7% | N/A |
| Return on Assets | -124.8%-42.3pp | -82.5%-54.4pp | -28.1% | N/A | -30.0%-6.5pp | -23.5%-2.7pp | -20.8% | N/A |
| Current Ratio | 1.39+0.2 | 1.15-0.2 | 1.35+0.4 | 0.97-1.1 | 2.08-0.3 | 2.39-1.1 | 3.51-0.3 | 3.86 |
| Debt-to-Equity | -1.76+5.3 | -7.02-7.5 | 0.52+0.0 | 0.51+0.2 | 0.34-0.1 | 0.41+0.0 | 0.37-0.0 | 0.39 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Moleculin Biotec profitable?
No, Moleculin Biotec (MBRX) reported a net income of -$33.6M in fiscal year 2025.
What is Moleculin Biotec's EBITDA?
Moleculin Biotec (MBRX) had EBITDA of -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Moleculin Biotec's return on equity (ROE)?
Moleculin Biotec (MBRX) has a return on equity of -223.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Moleculin Biotec's free cash flow?
Moleculin Biotec (MBRX) generated -$22.7M in free cash flow during fiscal year 2025. This represents a 4.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Moleculin Biotec's operating cash flow?
Moleculin Biotec (MBRX) generated -$22.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Moleculin Biotec's total assets?
Moleculin Biotec (MBRX) had $22.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Moleculin Biotec's capital expenditures?
Moleculin Biotec (MBRX) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Moleculin Biotec spend on research and development?
Moleculin Biotec (MBRX) invested $15.9M in research and development during fiscal year 2025.
What is Moleculin Biotec's current ratio?
Moleculin Biotec (MBRX) had a current ratio of 1.41 as of fiscal year 2025, which is considered adequate.
What is Moleculin Biotec's debt-to-equity ratio?
Moleculin Biotec (MBRX) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Moleculin Biotec's return on assets (ROA)?
Moleculin Biotec (MBRX) had a return on assets of -151.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Moleculin Biotec's cash runway?
Based on fiscal year 2025 data, Moleculin Biotec (MBRX) had $8.9M in cash against an annual operating cash burn of $22.7M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Moleculin Biotec's Piotroski F-Score?
Moleculin Biotec (MBRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Moleculin Biotec's earnings high quality?
Moleculin Biotec (MBRX) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.